A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan

Bristol-Myers Squibb (BMS)

Status

Completed

Conditions

Non-Valvular Atrial Fibrillation (NVAF)

Study type

Observational

Funder types

Industry

Identifiers

NCT05027061

CV185-771

Details and patient eligibility

About

The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.

Enrollment

11,776 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

• Participants received medical treatment for NVAF between 10-Jan-2012 and 31-Aug-2020.

Exclusion criteria

Had no data of serum creatinine in the participant's medical records
Had no data of body weight in the participant's medical records
Were given oral anticoagulant (OAC) for treatment of diseases other than atrial fibrillation (AF)

Other protocol-defined inclusion/exclusion criteria apply.